AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01518452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed JM working memory training after waiting
Description: Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
Study NCT03575039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaFlow II Transcatheter Aortic Valve System
Description: VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
Study NCT03090009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: 100 mg twice a day for 14 days
Study NCT03090009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo group
Study NCT03944486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Feasibility of OnTrack
Description: Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
Study NCT00877175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% tropicamide and 2.5% phenylephrine
Description: For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
Study NCT00877175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% tropicamide and 2.5% phenylephrine
Description: For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
Study NCT04841239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal topical formulation
Study NCT01965652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine 0.2 mg tablet taken orally once a day
Study NCT01965652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once a day
Study NCT04027010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy U tablet application
Description: There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms.
Study NCT03723590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esterified Hyaluronic Acid Matrix
Description: A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
Study NCT04164485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Functional collagen scaffold transplantation
Description: Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
Study NCT04164485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose cell transplantation
Description: Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
Study NCT03952156 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
Study NCT03952156 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HMI-102
Description: Control subjects will generally have the same assessments as treated subjects.~Control subjects will undergo pre-baseline procedures to confirm that they are eligible to receive treatment with HMI-102. Once eligible control subjects are dosed with HMI-102, they will initiate the same post-dose procedures as subjects who received HMI-102.
Study NCT01129154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusions of Panitumumab
Description: Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
Study NCT02416583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT04199117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Untailored outreach
Description: Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
Study NCT02416583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Study NCT02416583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane sweeping
Study NCT00884130 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic colorectal resection
Study NCT00884130 — intervention group
Intervention type: PROCEDURE
Intervention: open colorectal resection
Study NCT02466100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goals of care
Description: . Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
Study NCT03650400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fevipiprant
Description: Chewable tablet
Study NCT01195571 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: cmv vaccine
Description: dose escalation study of 4 towne-toledo chimera vaccines
Study NCT03721848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy community clinic NCD+MH
Description: NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures
Study NCT03721848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy community clinic NCD
Description: i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures
Study NCT04199117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple smoking cessation coaching calls
Description: Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
Study NCT04252482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 12 weeks
Study NCT02585258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 1 capsule containing a tablet of 5 mg prednisolone/ day
Study NCT02585258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule containing a placebo tablet / day
Study NCT02269202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, tablet
Study NCT02269202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam, tablet
Study NCT02269202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crobenetine, i.v. infusion
Study NCT02269202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04082975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: Oral dose for 7 days
Study NCT04082975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203-R
Description: Oral dose for 7 days
Study NCT04082975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1203 placebo
Description: Oral dose for 7 days
Study NCT04082975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203-R placebo
Description: Oral dose for 7 days
Study NCT01703741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel (FE 999093)
Study NCT03417622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bracketing
Description: At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
Study NCT03417622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bracketing
Description: At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
Study NCT03417622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
Study NCT03417622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
Study NCT03417622 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-treatment volume margin resection
Description: The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.
Study NCT03417622 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-treatment volume margin resection
Description: The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
Study NCT01900873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training
Description: IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
Study NCT01900873 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Endurance Training
Description: IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
Study NCT01139255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcasting + mobile media
Description: Use of a weight loss podcast designed with health behavior theory
Study NCT01139255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcasting + mobile media
Description: Use of a weight loss podcast designed with health behavior theory
Study NCT03242122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHO Control 1 and 2 Glucose
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
Study NCT03242122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 1 Slowly Digested
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
Study NCT03242122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 2 Digestion Resistant
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
Study NCT03242122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 3 Low Sugar
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
Study NCT03242122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHO Experimental 4 Maltodextrin
Description: mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
Study NCT01675908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Dysfunction
Description: Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
Study NCT01675908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complications
Description: Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
Study NCT04155697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorohexidine Gluconate soap
Description: Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
Study NCT04155697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 62% ethyl alcohol-based hand sanitizer
Description: Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
Study NCT03415971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG in a month after termination of treatment
Study NCT03415971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG in a 3 months after termination of treatment
Study NCT02984683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR566658 (ACT14884)
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study NCT01000584 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix, Vaxigrip 2009/2010
Description: Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
Study NCT00040859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00040859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00337805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pentaspan
Description: When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
Study NCT01433900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafluprost
Description: 1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
Study NCT01433900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: 1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
Study NCT04115449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
Study NCT04115449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline as a placebo will be infused over a period of ten minutes
Study NCT01000584 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arepanrix, Vaxigrip 2009/2010
Description: Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
Study NCT03052478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg
Description: Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
Study NCT00427648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alkalinized xylocaine
Description: 30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
Study NCT00427648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline
Study NCT02091089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite laser
Description: 755nm Alexandrite laser for the treatment of wrinkles
Study NCT04362176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pathogen reduced SARS-CoV-2 convalescent plasma
Description: Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
Study NCT04362176 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringer's solution with multivitamins
Study NCT01078376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (TAK-491)
Description: Azilsartan medoxomil 80 mg, tablets, orally, one day only
Study NCT00633152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftaroline
Description: 600 mg injected every 12 hours for at least 5 but not more than 14 days
Study NCT00633152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: 600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
Study NCT00633152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: 1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
Study NCT00401882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine (1 mg) IV additional doses
Study NCT00401882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
Study NCT01998685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT01998685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanyl
Study NCT01078376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (TAK-491)
Description: Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
Study NCT01078376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (TAK-491)
Description: Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
Study NCT00607789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg/day - 120 mg/day
Study NCT00607789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical to study drug
Study NCT01998685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01998685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT01998685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study NCT05001490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application based reminder
Description: Brushing reminders were given to the patients in experimental group through a smartphone application twice daily